NVS vs ZBIO
NVS: Global pharmaceutical and biotechnology company pioneering disease-modifying treatments across oncology, immunology, neuroscience, and rare genetic diseases. ZBIO: Clinical-stage immunology company developing obexelimab, a novel bifunctional monoclonal antibody targeting B cells for the treatment of autoimmune diseases.
Side-by-side fundamentals
| Metric | NVS | ZBIO | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $158.86 | $32.29 | |
| Market cap as of 2026-08-24 | $227.4B | $2.1B | |
| P/E as of 2026-08-24 | 21.95 | n/a | |
| PEG as of 2026-08-24 | 3.66 | -0.10 | ZBIO lower |
| Net margin as of 2026-08-24 | +22.5% | -3777.4% | NVS higher |
| Gross margin as of 2026-08-24 | +75.0% | n/a | |
| Operating margin as of 2026-08-24 | +29.9% | -3830.6% | NVS higher |
| ROE as of 2026-08-24 | +29.9% | -167.7% | NVS higher |
| ROA as of 2026-08-24 | +11.1% | -97.4% | NVS higher |
| Debt / equity as of 2026-08-24 | 1.18 | 1.04 | ZBIO lower |
| Revenue growth (YoY) as of 2026-08-24 | +3.3% | n/a | |
| Revenue CAGR (3y) SEC XBRL | n/a | -55.3% | |
| Dividend yield as of 2026-08-24 | +3.7% | n/a | |
| Beta as of 2026-08-24 | 1.17 | 0.70 | |
| 1-year return as of 2026-08-21 close | +25.3% | +90.7% | ZBIO higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.